We came across a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) on Kontra Investment Xchange’s Substack by ...

Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine ...

Turkey was offered partner country status by the BRICS group of nations, Trade Minister Omer Bolat said, as Ankara continues ...

Alvotech and Teva Pharmaceuticals announced that the U.S. FDA has approved ... Bangladesh and Pakistan), YAS Holding LLC ...

Teva Pharmaceutical ( (TEVA)) has provided an update. Teva Pharmaceutical Industries has appointed Chen Lichtenstein as a new independent Board member, effective December 1, 2024. With a robust ...

Teva Pharmaceutical Industries raised its 2024 revenue and earnings guidance after beating third-quarter profit forecasts, boosted by strong sales of copycat medicines and its branded drugs to treat ...

About AVT23 AVT23 is a monoclonal antibody and proposed biosimilar to Xolair ® (omalizumab). AVT23 is an investigational compound and has not received regulatory approval in any country. Biosimilarity ...

The North Ireland Protocol has been a source of tension between the UK and EU since it came into force at the start of 2021 – and, according to one pharma ... the protocol, Teva UK called ...

European Union antitrust authorities fined Israel’s Teva Pharmaceuticals TEVA1.92%increase; green up pointing triangle 462.6 million euros ($502.3 million), saying the company abused its market ...

"Today's decision to impose an antitrust fine on Teva for disparagement and misuse of the patent system reaffirms the commission's commitment to competition enforcement in the pharmaceutical sector," ...

Twelve years ago Democrats won a surprising two-thirds supermajority in the state Legislature, giving themselves the strength to pass any bill without the need for a single ...

The European Commission has fined Teva , the world's largest generic drugmaker, 462.6 million euros ($503 million) for abusing its dominant position to delay competition to its blockbuster multiple ...